From: Horizontal augmentation techniques in the mandible: a systematic review
Author | Gender | Age (y) | Inclusion criteria | Exclusion criteria | Smoking | Systemic condition | Implant placement after augmentation (mths) | Types of implants | Mean follow-up (mths) |
---|---|---|---|---|---|---|---|---|---|
Amorfini et al. [101] | – | Median 59.5 (32–72) | Adult patients; bilateral atrophic edentulous areas in the posterior mandible | Systemic diseases affecting the bone metabolism | n/a | No systemic condition affecting bone metabolism | Simultaneous | SLActive; Straumann (Basel, Switzerland) | 12 |
Barbu et al. [100] | 13 female; 11 male | Mean 47.8 (24–71) | At least 10-mm residual height, but less than 4.3-mm bucco-lingual dimension | Smoking; uncontrolled systemic disease; active periodontal disease | Excluded | No uncontrolled systemic disease | 4 | TSV Zimmer Dental Inc (Carlsbad, California, USA) | 19.8 |
Beitlitum et al. [117] | 12 female; 3 male | Mean 53 (36–68) | Mandibular partial edentulism, horizontal bone deficiency that prevented implant placement | Presence of uncontrolled periodontal disease involving the residual dentition, an active endodontic condition involving the adjacent teeth | > 10cig/d excluded | No pregnancy or lactation, bone disease or medication interfering with bone metabolism, history of head and neck radiotherapy, metabolic disorders (eg, uncontrolled diabetes mellitus), immunodeficiency | 5–7 | – | 6 |
Di Stefano et al. [104] | 3 female; 2 male | Mean 45.5 (32–59) | Crestal width ≤ 4 mm, crestal height ≥ 10 mm, age > 30 years, controlled oral hygiene and absence of lesions | High degree of bruxism; excessive consumption of alcohol; localized radiation therapy of the oral cavity; inflammatory and autoimmune diseases of the oral cavity; and poor oral hygiene | > 10cig/d excluded | No antineoplastic chemotherapy; blood, liver, and kidney diseases; immunosuppression; corticosteroids and bisphosphonates therapy; pregnancy; | 6 | XiVE, Dentsply-Friadent, (Mannheim, Germany) | 40.5 |
Nissan et al. [103] | 18 female; 3 male | Mean 55.7 | Patients with a mandibular alveolar ridge requiring a vertical and lateral augmentation of > 3 mm patients in good health | Contraindications to implant therapy | n/a | Healthy | 6 | Seven; MIS® (Savion, Israel) or Osseotite; Zimmer Biomet 3i (Warsaw, USA) | 37 ± 17 |
Schwartz-Arad et al. [99] | – | 50.3 | Edentulous mandibular area with degree of atrophy preventing placement of implants of at least 6 mm in height without the risk of damaging anatomical structures | Poor oral hygiene noncompliance | 18.2% | Exclusion of kidney/liver/connective tissue disease, immunodeficiency, chemotherapy, radiotherapy | 5 | Screw-Vent and Spline; Zimmer Biomet 3i, (Warsaw, USA) or NobelActive and Replace Select, Nobel Biocare (Goteborg, Sweden) or Implant Direct (Zurich, Switzerland) | 39.9 ± 30.9 |
Silva et al. [105] | 15 female; 5 male | Mean 51.8 (37–64) | Alveolar ridge width and/or height ≤ 6 mm; > 18 yrs. Good oral health, no active periodontal disease, or occlusal problems | Compromised oral or general health, pregnancy, alcohol abuse, radiotherapy, bisphosphonates | Excluded | Good general and mental health | 6 | TitamaxCM Cortical, Neodent, (Curitiba, Brazil) | 31.8 ± 7 |
Urban et al. [102] | 9 female; 3 male | 51.4 | Horizontal ridge of 4 mm or less, Cawood Howell Class IV, ability to maintain good oral hygiene | Smokers, patients with alcohol abuse, periodontal disease | Excluded | Systemically and periodontally healthy | 6.9 | Implants with an anodized TiUnite surface (Brånemark System, Nobel Biocare) | 20.9 ± 9.5 |